{"id":48300,"date":"2022-09-13T14:01:48","date_gmt":"2022-09-13T12:01:48","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/"},"modified":"2022-09-13T14:01:48","modified_gmt":"2022-09-13T12:01:48","slug":"wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/","title":{"rendered":"WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research"},"content":{"rendered":"<div>\n<p>PRINCETON, N.J. &amp; OVERLAND PARK, Kan.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.wcgirb.com%2F&amp;esheet=52883549&amp;newsitemid=20220913005170&amp;lan=en-US&amp;anchor=WCG&amp;index=1&amp;md5=7de33e779a439af9771358762a824df8\" rel=\"nofollow noopener\" shape=\"rect\">WCG<\/a>, the world\u2019s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing purpose-built operations for Phase I investigators. Launched in conjunction with the opening of <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdrvince.com%2F&amp;esheet=52883549&amp;newsitemid=20220913005170&amp;lan=en-US&amp;anchor=Dr.+Vince+Clinical+Research%26%238217%3Bs+%28DVCR%29&amp;index=2&amp;md5=f7599507ad15eb45624e6b685d607693\" rel=\"nofollow noopener\" shape=\"rect\">Dr. Vince Clinical Research\u2019s (DVCR)<\/a> industry-leading, green-designed research complex in Overland Park, Kansas \u2014 who selected WCG as their institutional review board (IRB) of record \u2014 these expanded services will provide<i> <\/i>faster timelines in the clinical trial process without sacrificing superior levels of human subject protection for early stage and clinical pharmacology research.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220913005170\/en\/1568560\/5\/WCG_DVCR_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220913005170\/en\/1568560\/21\/WCG_DVCR_logo.jpg\"><\/a><\/p>\n<p>\n\u201cThis expansion enables early phase research to complete in more predictable fashion and ensures participant protection through every stage of the study,\u201d said <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.wcgirb.com%2Fleadership%2Fmark-mcdonald%2F&amp;esheet=52883549&amp;newsitemid=20220913005170&amp;lan=en-US&amp;anchor=Mark+McDonald&amp;index=3&amp;md5=b8de56b4e4a3cf0c211a5374d1886cbb\" rel=\"nofollow noopener\" shape=\"rect\">Mark McDonald<\/a>, president of WCG IRB. \u201cBased on the high propensity for changes in first in human research, sponsors are adding cohorts and doses to study designs which often increases the need for additional amendments to the study protocol, ultimately contributing to the frequency of delays. Implementing customized operational teams that focus on providing efficient, high-quality processing services, speeding up the operations while maintaining focus on thorough board reviews, allows WCG IRB to fundamentally change the way Phase I research is executed.\u201d\n<\/p>\n<p>\nWith the introduction of this new model, clients will:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nBenefit from dedicated operations to support accelerated processing of submissions in preparation for IRB review\n<\/li>\n<li>\nContinue to recognize the benefits from WCG\u2019s over 50 years of unparalleled expertise\n<\/li>\n<li>\nHave a single point of contact who will be available to address questions and help clients navigate the IRB process\n<\/li>\n<li>\nReceive timely review of IRB submission materials with a board that convenes daily and delivers predictable turnaround times for all study items\n<\/li>\n<\/ul>\n<p>\nWith more than 20 years of experience in the clinical research industry, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdrvince.com%2Four-founder%2F&amp;esheet=52883549&amp;newsitemid=20220913005170&amp;lan=en-US&amp;anchor=Dr.+Brad+Vince&amp;index=4&amp;md5=1e751ac72d95cb9b0dda252383683f4f\" rel=\"nofollow noopener\" shape=\"rect\">Dr. Brad Vince<\/a>, CEO and medical director of DVCR, has served as an investigator in over 600 clinical trials and authored numerous scientific publications.\n<\/p>\n<p>\n\u201cIt\u2019s our vision to create one of the most innovative and technologically advanced Phase I units in the world,\u201d said Dr. Vince. \u201cThe ability to accelerate study timelines while maintaining the highest degree of study volunteer safety was the key factor in selecting WCG IRB, the largest and most trusted central IRB in the U.S., for our early phase clinical trials.\u201d\n<\/p>\n<p>\n<b>About WCG<\/b>\n<\/p>\n<p>\nWCG is the world\u2019s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry\u2019s first central IRB \u2014 WCG IRB \u2014 and first clinical services organization, WCG enables biopharmaceutical companies, CROs and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.wcgirb.com&amp;esheet=52883549&amp;newsitemid=20220913005170&amp;lan=en-US&amp;anchor=www.wcgirb.com&amp;index=5&amp;md5=45023e9f4c00fbbacecae0d89b552064\" rel=\"nofollow noopener\" shape=\"rect\">www.wcgirb.com<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.wcgclinical.com&amp;esheet=52883549&amp;newsitemid=20220913005170&amp;lan=en-US&amp;anchor=www.wcgclinical.com&amp;index=6&amp;md5=2725101160285fc1a734a1a19d3b335a\" rel=\"nofollow noopener\" shape=\"rect\">www.wcgclinical.com<\/a> or follow us on Twitter <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fwcgclinical%3Flang%3Den&amp;esheet=52883549&amp;newsitemid=20220913005170&amp;lan=en-US&amp;anchor=%40WCGClinical&amp;index=7&amp;md5=ecf5bd1b370e46961c7639e3c5c53fc6\" rel=\"nofollow noopener\" shape=\"rect\">@WCGClinical<\/a> or LinkedIn.\n<\/p>\n<p>\n<b>About Dr. Vince Clinical Research<\/b>\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdrvince.com%2F&amp;esheet=52883549&amp;newsitemid=20220913005170&amp;lan=en-US&amp;anchor=Dr.+Vince+Clinical+Research+%28DVCR%29&amp;index=8&amp;md5=1415873f1889a5ebcf6fc11dc1ce4b0f\" rel=\"nofollow noopener\" shape=\"rect\">Dr. Vince Clinical Research (DVCR)<\/a> is a world-class CRO (Contract Research Organization) with a custom-built, green-designed headquarters and research complex encompassing three buildings in Overland Park, KS. DVCR\u2019s complex includes a 90-bed clinical pharmacology unit featuring a combination of luxurious and private research suites and a GMP compliant pharmacy with positive and negative pressure compounding rooms. DVCR specializes in conducting clinical trials for both healthy normal volunteers and patient populations in a wide variety of early phase trials. By leveraging both technology and one of the country\u2019s most experienced leadership teams, DVCR provides Smarter, Faster Data\u2122 to their biopharmaceutical clients.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nCarmin Gade, Ph.D.<br \/>\n<br \/>Chief Marketing Officer<br \/>\n<br \/>484-351-9959<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#116;&#111;:cg&#x61;&#x64;&#x65;&#x40;&#119;&#99;gcl&#x69;&#x6e;&#x69;&#x63;&#97;&#108;&#46;co&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;&#x67;&#97;d&#x65;&#x40;&#119;cg&#x63;&#x6c;&#105;n&#x69;&#x63;&#97;&#108;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PRINCETON, N.J. &amp; OVERLAND PARK, Kan.&#8211;(BUSINESS WIRE)&#8211;WCG, the world\u2019s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing purpose-built operations for Phase I investigators. Launched in conjunction with the opening of Dr. Vince Clinical Research\u2019s (DVCR) industry-leading, green-designed research &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48300","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J. &amp; OVERLAND PARK, Kan.&#8211;(BUSINESS WIRE)&#8211;WCG, the world\u2019s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing purpose-built operations for Phase I investigators. Launched in conjunction with the opening of Dr. Vince Clinical Research\u2019s (DVCR) industry-leading, green-designed research ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T12:01:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220913005170\/en\/1568560\/21\/WCG_DVCR_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research\",\"datePublished\":\"2022-09-13T12:01:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/\"},\"wordCount\":602,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005170\\\/en\\\/1568560\\\/21\\\/WCG_DVCR_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/\",\"name\":\"WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005170\\\/en\\\/1568560\\\/21\\\/WCG_DVCR_logo.jpg\",\"datePublished\":\"2022-09-13T12:01:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005170\\\/en\\\/1568560\\\/21\\\/WCG_DVCR_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005170\\\/en\\\/1568560\\\/21\\\/WCG_DVCR_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/","og_locale":"en_US","og_type":"article","og_title":"WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research - Pharma Trend","og_description":"PRINCETON, N.J. &amp; OVERLAND PARK, Kan.&#8211;(BUSINESS WIRE)&#8211;WCG, the world\u2019s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing purpose-built operations for Phase I investigators. Launched in conjunction with the opening of Dr. Vince Clinical Research\u2019s (DVCR) industry-leading, green-designed research ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-13T12:01:48+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220913005170\/en\/1568560\/21\/WCG_DVCR_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research","datePublished":"2022-09-13T12:01:48+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/"},"wordCount":602,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220913005170\/en\/1568560\/21\/WCG_DVCR_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/","url":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/","name":"WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220913005170\/en\/1568560\/21\/WCG_DVCR_logo.jpg","datePublished":"2022-09-13T12:01:48+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220913005170\/en\/1568560\/21\/WCG_DVCR_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220913005170\/en\/1568560\/21\/WCG_DVCR_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/wcg-irb-expands-phase-i-review-services-partners-with-dr-vince-clinical-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"WCG IRB Expands Phase I Review Services, Partners With Dr. Vince Clinical Research"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48300"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48300\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}